| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Aganepag isopropyl is a prodrug that is metabolized to its active form, aganepag. Aganepag targets the prostanoid EP2 receptor, a G protein-coupled receptor that mediates the effects of prostaglandin E2 (PGE2). Activation of EP2 receptors leads to vasodilation and increased aqueous humor outflow, thereby reducing intraocular pressure (IOP).
|
|---|---|
| ln Vitro |
AGN-210961, also known as aganepag isoryl, is an EP2 agonist[1] [2].
In vitro, Aganepag isopropyl is a prodrug that is converted to aganepag. The active metabolite, aganepag, is a potent and selective EP2 receptor agonist. Its activity is typically measured using cell-based functional assays, such as cAMP accumulation assays in cells expressing the EP2 receptor. These assays confirm the compound's activity as a prodrug of an EP2 receptor agonist. |
| ln Vivo |
In vivo, Aganepag isopropyl is currently under clinical investigation for its safety, efficacy, and IOP-lowering potential in ophthalmic therapy. It is being studied in clinical trial NCT01110499 (AGN-210961: Comparison of the safety and efficacy of ophthalmic solutions with bimatoprost ophthalmic solutions in patients with glaucoma or ocular hypertension).
|
| Enzyme Assay |
In vitro enzyme assays for Aganepag isopropyl measure its conversion to the active metabolite, aganepag. The compound is incubated with esterases or tissue homogenates, and the release of aganepag is monitored by HPLC. These assays confirm the prodrug nature of Aganepag isopropyl.
|
| Cell Assay |
In vitro cell-based assays for Aganepag isopropyl are used to study the effects of its active metabolite, aganepag, on EP2 receptor signaling. Cells expressing the EP2 receptor are treated with Aganepag isopropyl or aganepag, and the accumulation of cAMP is measured. The EC50 is determined from dose-response curves. These assays confirm the compound's activity as a prodrug of an EP2 receptor agonist.
|
| Animal Protocol |
In vivo animal experiments for Aganepag isopropyl have been conducted in animal models of glaucoma. In a typical study, the compound is administered topically to the eyes of animals with elevated IOP. The reduction in IOP is measured over time. The compound's efficacy is compared to that of other IOP-lowering agents.
|
| ADME/Pharmacokinetics |
In vitro enzyme assays for Aganepag isopropyl measure its conversion to the active metabolite, aganepag. The compound is incubated with esterases or tissue homogenates, and the release of aganepag is monitored by HPLC. These assays confirm the prodrug nature of Aganepag isopropyl.
|
| Toxicity/Toxicokinetics |
In vitro cell-based assays for Aganepag isopropyl are used to study the effects of its active metabolite, aganepag, on EP2 receptor signaling. Cells expressing the EP2 receptor are treated with Aganepag isopropyl or aganepag, and the accumulation of cAMP is measured. The EC50 is determined from dose-response curves. These assays confirm the compound's activity as a prodrug of an EP2 receptor agonist.
|
| References | |
| Additional Infomation |
Aganepag isopropyl belongs to the pyrrolidine class of compounds. Aganepag isopropyl is currently being studied in the clinical trial NCT01110499 (AGN-210961: Comparison of the safety and efficacy of ophthalmic solutions with bimatoprost ophthalmic solutions in patients with glaucoma or ocular hypertension).
Aganepag isopropyl has a molecular weight of 471.65 g/mol and a molecular formula of C27H37NO4S. It has a CAS number of 910562-20-8. For storage, it is recommended to keep the compound in a cool, dry place. Pharmacokinetic properties such as absorption, distribution, metabolism, and excretion (ADME) have been characterized in the context of clinical development. |
| Molecular Formula |
C27H37NO4S
|
|---|---|
| Molecular Weight |
471.66
|
| Exact Mass |
471.244
|
| CAS # |
910562-20-8
|
| PubChem CID |
46928007
|
| Appearance |
Colorless to light yellow ointment
|
| LogP |
6.51
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
33
|
| Complexity |
619
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
S1C(C(=O)OC(C)C)=CC=C1CCC[C@H]1CCC(N1C1C=CC(=CC=1)[C@H](CCCCC)O)=O
|
| InChi Key |
GKRBCKDGBDUAIQ-URXFXBBRSA-N
|
| InChi Code |
InChI=1S/C27H37NO4S/c1-4-5-6-10-24(29)20-11-13-22(14-12-20)28-21(15-18-26(28)30)8-7-9-23-16-17-25(33-23)27(31)32-19(2)3/h11-14,16-17,19,21,24,29H,4-10,15,18H2,1-3H3/t21-,24-/m0/s1
|
| Chemical Name |
propan-2-yl 5-[3-[(2S)-1-[4-[(1S)-1-hydroxyhexyl]phenyl]-5-oxopyrrolidin-2-yl]propyl]thiophene-2-carboxylate
|
| Synonyms |
Aganepag isopropyl AGN 210961 AGN-210961 AGN210961
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 200 mg/mL (~424.04 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1202 mL | 10.6009 mL | 21.2017 mL | |
| 5 mM | 0.4240 mL | 2.1202 mL | 4.2403 mL | |
| 10 mM | 0.2120 mL | 1.0601 mL | 2.1202 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
